Thanks for your insights, but Vical is designed to be a therapeutic vaccine, not a cure as with Frazer's. It doesn't appear to be much more effective than valocyclovir (Valtrex) in initiating adequate T cell response.
Yes, there is plenty of competition. But Coridon's codon optimisation tech puts us ahead as it can be implemented to target a range of other viruses.
updated ballieu report - target range 25-55c, page-53
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |